Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Dihedral - D2  (3D View)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 192.27 kDa 
• Atom Count: 13232 
• Modelled Residue Count: 1666 
• Deposited Residue Count: 1764 
• Unique protein chains: 1

3BGL

Hepatoselectivity of Statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors

• DOI: 10.2210/pdb3BGL/pdb

• Classification: OXIDOREDUCTASE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): Yes 


• Deposited: 2007-11-26 Released: 2008-01-29 
• Deposition Author(s): Finzel, B.C., Pavlovsky, A., Park, W.K.C.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.23 Å
• R-Value Free: 0.251 
• R-Value Work: 0.208 
• R-Value Observed: 0.210 

Literature

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Park, W.K., Kennedy, R.M., Larsen, S.D., Miller, S., Roth, B.D., Song, Y., Steinbaugh, B.A., Sun, K., Tait, B.D., Kowala, M.C., Trivedi, B.K., Auerbach, B., Askew, V., Dillon, L., Hanselman, J.C., Lin, Z., Lu, G.H., Robertson, A., Sekerke, C.

(2008) Bioorg Med Chem Lett 18: 1151-1156

• PubMed: 18155906 
• DOI: 10.1016/j.bmcl.2007.11.124
• Primary Citation of Related Structures:  
  3BGL


• PubMed Abstract: 
  

4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3+2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and ClogP values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.

---

Organizational Affiliation: 

Department of Chemistry, CVMED, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI, USA. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
3-hydroxy-3-methylglutaryl-coenzyme A reductase	A, B, C, D	441	Homo sapiens	Mutation(s): 1  Gene Names: HMGCR EC: 1.1.1.34
Find proteins for P04035 (Homo sapiens) Explore P04035  Go to UniProtKB:  P04035
NIH Common Fund Data Resources
PHAROS:  P04035 GTEx:  ENSG00000113161

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
RID	E [auth A], F [auth B], G [auth C], H [auth D]	(3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-4-(morpholin-4-ylsulfonyl)-3-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid C30 H37 F N2 O7 S XLVZRBHNHHAPDT-JWQCQUIFSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
RID	IC50:  4.5   nM  Binding MOAD
RID	IC50 :  4.5   nM  PDBBind

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.23 Å
• R-Value Free: 0.251 
• R-Value Work: 0.208 
• R-Value Observed: 0.210 
• Space Group: P 1 2₁ 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 71.588	α = 90
b = 172.156	β = 117.24
c = 75.148	γ = 90

Software Package:

Software Name	Purpose
DENZO	data reduction
SCALEPACK	data scaling
REFMAC	refinement
PDB_EXTRACT	data extraction
HKL-2000	data reduction
HKL-2000	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2007-11-26 
• Released Date: 2008-01-29 
Deposition Author(s): Finzel, B.C., Pavlovsky, A., Park, W.K.C.

Revision History  

• Version 1.0: 2008-01-29
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Version format compliance
• Version 1.2: 2017-10-25
  Changes: Refinement description